Alessia Petrocchi

An inhibitor of oxidative phosphorylation exploits cancer vulnerability

Jennifer R. Molina, Yuting Sun, Marina Protopopova et al. · Nature Medicine · 2018 · 903 citations · Full text

Medicine, Anti-cancer Agent, Cancer Vulnerability +4

Discovery of Raltegravir, a Potent, Selective Orally Bioavailable HIV-Integrase Inhibitor for the Treatment of HIV-AIDS Infection

Vincenzo Summa, Alessia Petrocchi, Fabio Bonelli et al. · Journal of Medicinal Chemistry · 2008 · 624 citations · Full text

Antiviral Drug, Medicinal Chemistry, Antiviral Drug Development +16

The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies

Bhavatarini Vangamudi, Thomas A. Paul, Parantu K. Shah et al. · Cancer Research · 2015 · 266 citations · Full text

Atpase Domain, Exclusive Catalytic Subunits, Drug Target +17

Discovery of MK-5172, a Macrocyclic Hepatitis C Virus NS3/4a Protease Inhibitor

Steven J. Harper, John A. McCauley, Michael T. Rudd et al. · ACS Medicinal Chemistry Letters · 2012 · 201 citations · Full text

Immunology, Molecular Biology, Pharmacotherapy +19

Structure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor

Wylie S. Palmer, G. Poncet-Montange, Gang Liu et al. · Journal of Medicinal Chemistry · 2015 · 152 citations · Full text

Combinatorial Chemistry, Epigenetic Change, X-ray Cocrystal Structures +20